Sanofi takes $2B hemophilia write-down by Carly Helfand Monday, July 29, 2019 It’s been just 16 months since Sanofi closed its Bioverativ buy, but it's already revising its sales projections for one of Bioverativ’s key products.
How can new launches mimic Keytruda, Harvoni and Opdivo? by Eric Sagonowsky Thursday, November 16, 2017 In just a few years, pharma's top launches of 2014 have amassed huge sales and reshaped treatment—and they're now among the biggest launches ever.
